# MINDIMMUNE THERAPEUTICS, INC.: Targeting CD11c immune cells to alleviate cerebral amyloid angiopathy and amyloid-related imaging abnormality in patients with Alzheimer's disease

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | MINDIMMUNE THERAPEUTICS, INC. |
| Location | KINGSTON, RI |
| Project | Targeting CD11c immune cells to alleviate cerebral amyloid angiopathy and amyloid-related imaging abnormality in patients with Alzheimer's disease |
| Project number | 1R43AG102103-01 |
| Mechanism | R43 |
| Institute | National Institute on Aging |
| Award | $496,415 |
| Awarded | 2026-09-17 |
| Project period | 2026-09-22 to 2027-09-21 |
| UEI | DDPZS2FUTEK3 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11406463). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.